Tesamorelin
Tesamorelin 10 mg is a research peptide studied for its activity at the growth hormone-releasing hormone pathway and its downstream effects on growth hormone and IGF-1 signaling. Research has explored tesamorelin in areas including visceral adipose tissue, body composition, lipid metabolism, and broader metabolic health pathways.
For research use only. Not for human consumption.
Visceral fat and liver fat randomized clinical trial
Looked at tesamorelin’s effects on visceral adipose tissue, liver fat, and metabolic measures in people with HIV-associated abdominal fat accumulation.
Growth hormone-releasing factor and metabolic effects
A large randomized study examining visceral fat, triglycerides, cholesterol measures, and IGF-1.
Phase 3 randomized placebo-controlled trial
Studied visceral adipose tissue, waist measures, IGF-1, body composition, and glucose parameters.
2026 meta-analysis of randomized trials
Reviews effects on visceral fat, hepatic fat, lean body mass, IGF-1, and other metabolic outcomes.
